Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Biogen Shares Drop as Tysabri PML Cases Climb to 23, Europe May Seek Drug ‘Holiday’
|
Luke Timmerman |
10/23/09 |
Boston
|
|
Tysabri’s Tally of PML Cases Reaches 13
|
Luke Timmerman |
09/17/09 |
Boston
|
|
Elan Breached Tysabri Partnership With Biogen Idec, Federal Judge Says
|
Luke Timmerman |
09/04/09 |
Boston
|
|
Biogen Idec Faces Suit From Partner Elan, Genzyme Wins European Approval for Stem-Cell Boosting Drug, Alnylam Teams with Tekmira, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
08/12/09 |
Boston
|
|
Elan Hits Biogen Idec with Lawsuit to Protect Tysabri Deal with J&J
|
Ryan McBride |
08/06/09 |
Boston
|
|
Biogen Gets Int’l Rights to Acorda’s MS Drug
|
Roxanne Palmer |
07/01/09 |
Boston
|
|
Biogen Reports 10th PML Case in Tysabri Patient
|
Roxanne Palmer |
06/29/09 |
Boston
|
|
Biogen Idec Showdown with Carl Icahn Culminates in Shareholder Vote Today
|
Luke Timmerman |
06/03/09 |
Boston
|
|
Icahn’s Plan to Split Up Biogen Idec Would “Destroy Shareholder Value,” Company Says
|
Luke Timmerman |
05/15/09 |
Boston
|
|
Avila Therapeutics Hires First CEO Katrine Bosley, Adds $5M from Existing Investors
|
Ryan McBride |
05/15/09 |
Boston
|
|
Biogen Idec Pipeline Strong, Tysabri Coming Back; Icahn Would “Weaken” Board, Company Says
|
Luke Timmerman |
05/14/09 |
Boston
|
|
Taligen Raises $26M For Inflammation Drugs
|
Luke Timmerman |
05/12/09 |
Boston
|
|
Icahn Throws Down the Gauntlet, Attacks Biogen Idec’s “Failed Leadership”
|
Luke Timmerman |
05/11/09 |
Boston
|
|
Tysabri May Promote Healing Around Nerves, Study Says
|
Luke Timmerman |
04/28/09 |
Boston
|
|
Biogen Idec To Show Off MS Drugs at Seattle Neurology Meeting
|
Luke Timmerman |
04/24/09 |
Boston
|
|
Biogen Idec Tysabri Sales Fall Shy of Street Expectations
|
Luke Timmerman |
04/16/09 |
Boston
|
|
FDA Allows High-Yield Tysabri Production
|
Ryan McBride |
04/16/09 |
Boston
|
|
Rematch Time: Carl Icahn and Biogen Idec Square Off Again
|
Luke Timmerman |
04/14/09 |
Boston
|
|
Carl Icahn Aims to Stick “For Sale” Sign on Biogen Idec Lawn Again
|
Luke Timmerman |
02/06/09 |
Boston
|
|
Biogen Idec Rival Succeeds in Trial of Oral Pill for Multiple Sclerosis
|
Luke Timmerman |
01/23/09 |
Boston
|
|
Seattle’s Top 10 Innovation Stories of the Half-Year (and Others We Just Plain Liked)
|
Gregory T. Huang |
12/31/08 |
Seattle
|
|
New RNAi Drugs, Major Cutbacks at Targanta, Big Partnerships for Arqule and Archemix, & More Boston-Area Life Sciences News
|
Wade Roush |
12/24/08 |
Boston
|
|
Tysabri Patient Dies of Brain Infection, First Death Since Drug Re-Introduced
|
Luke Timmerman |
12/19/08 |
Boston
|
|
Tysabri Patient Diagnosed With PML
|
Luke Timmerman |
12/15/08 |
Boston
|
|
Biogen Idec VC Group Sees Opportunity in Tough Market, Has $100M New Allocation to Invest in Biotech Firms
|
Ryan McBride |
12/12/08 |
San Diego
|
|
Tysabri’s Roots at the “Hutch,” MediQuest Spurned by FDA, ZymoGenetics Drug Passes Test, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
11/06/08 |
Seattle
|
|
A Trio of Tysabri Stories, Genzyme’s Big Deal with Osiris, A Peek Inside a Winning Hedge Fund, & More Life Sciences News
|
Rebecca Zacks |
11/05/08 |
Boston
|
|
Tysabri: The Big Multiple Sclerosis Drug That Emerged From “The Hutch”
|
Luke Timmerman |
11/04/08 |
Seattle
|
|
Democratic Party Fundraiser Dies, After Friends and Family Pushed To Get Him Tysabri
|
Luke Timmerman |
10/31/08 |
Boston
|
|
Biogen Idec, Elan’s Tysabri Linked to First U.S. Case of Brain Infection
|
Luke Timmerman |
10/29/08 |
Boston
|
|
Page 1 of
2 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
